Navigation Links
Actos Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of Next Status Conference in Federal Actos Bladder Cancer Litigation
Date:9/14/2013

der cancer last year, alleges that Takeda knew as early as 2005 that research had linked prolonged use of the drug to the disease cancer, but waited six years to issue a public warning. The complaint further alleges that the company’s conduct was motivated by a desire to increase Actos sales. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)

The first trial involving Actos and bladder cancer concluded this past April in Los Angeles Superior court, with that jury awarding more than $6 million to a man who was diagnosed with bladder cancer after taking Actos for four years. However, court documents indicate that the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

The litigation involving Actos bladder cancer claims began to move forward in June 2011, after the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year could increase a patient’s risk for the disorder. At that time, the FDA mandated that new information about the association between Actos and bladder cancer be added to the drug’s label.

Patients who took Actos for an extended period of time and later developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based la
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. After Taking Diabetes Drug Actos for Nearly Seven Years, Florida Man Developed Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
2. Actos Lawsuit Filed By Wright & Schulte on Behalf of Ohio Man Alleges Extended Use of Type-2 Diabetes Drug Caused Him to Develop Bladder Cancer
3. Actos Bladder Cancer Lawsuits Move Forward, with Issuance of New Order in Federal Actos Litigation, Bernstein Liebhard LLP Reports
4. Lawsuit Alleges Takeda Pharmaceutical Co., Maker of Diabetes Drug Actos, Didn’t Warn of the Drug’s Risks Soon Enough; Parker Waichman LLP Responds
5. Actos Lawsuit News: Bernstein Liebhard LLP Notes Start of Second Actos Bladder Cancer Trial in Maryland State Court
6. Actos Bladder Cancer Lawsuits Help: Resource4thePeople Reports Number of Consolidated Federal Cases Climbs to over 2,500
7. Actos Lawsuits Move Forward Following Latest Status Conference in Federal Actos Bladder Cancer Litigation
8. Oregon Man Developed Bladder Cancer Brought on by Years of Ingesting Diabetes Drug Actos, Alleges Lawsuit Filed by Parker Waichman LLP
9. Florida Woman Developed Bladder Cancer After Taking Actos to Treat her Type II Diabetes, Alleges Lawsuit Filed by Parker Waichman LLP
10. Years of Ingesting Diabetes Drug Actos Caused Florida Man to Develop Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
11. Actos Lawsuits Alleging Bladder Cancer Update: Resource4thePeople Reports Judge Continues to Move Multidistrict Litigation Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... United States with 1 in 68 children currently affected with the disorder. For ... child on the road to recovery is extremely daunting. That’s where Talk About ...
(Date:7/28/2015)... FL (PRWEB) , ... July 16, 2015 (PRWEB) ... ... Insurance Agency, in Miami, FL, that specializes in providing Health insurance quotes to ... multiple carriers clients compare auto insurance rates that best suits their specific needs. ...
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave ... took place from noon to 1 p.m. Tuesday, June 23, at the Gulf Coast ... , Dr. Ahmad is board-certified in colorectal surgery and has more than 35 years ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser Institute in Anaheim ... smooth state, and reduces the appearance of fine lines and wrinkles. , According to ... to instantly add volume to your cheek area to correct age-related volume loss in ...
(Date:7/28/2015)... ... , ... According to WFTV on July 15th heroin overdose rates ... cases. According to recent statistic Orlando suffers at least one death weekly as a ... heroin, and law enforcement officials are struggling to keep apace with its distribution. Officers ...
Breaking Medicine News(10 mins):Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:Nations Insurance Solutions Announces Auto, Motorcycle, and Commercial Business Insurance Quotes. 2Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3
... some experts, newly born neuronal stem cells in the adult ... these stem cells are to be utilized in this way, ... regulated. , A new study, led by Laurence Katz, ... of the North Carolina School of Medicine, suggests a way ...
... FALLS" , A study by Indiana University ... of their elderly study participants and their postural stability ... in line with recent findings by other researchers involving ... designed to probe cognitive function effective at identifying people ...
... of American,Physicians, Inc. (CAP) today announced that the exceptional ... has again,earned an A+ rating from A.M. Best Company, ... consecutive year that MPT has,achieved this rating., "We ... Rating again this year,",said CEO James L. Weidner. "It ...
... to millions of diabetics who are missed , , FRIDAY, ... for diabetes is being called for to help the ... disease, a new report says. , "Approximately 30 percent ... undiagnosed," study author Dr. Christopher Saudek, of Johns Hopkins ...
... & Asthma Network Mothers of Asthmatics Applauds FDA Public ... and Offers Critical Facts Patients Need to Know, ... their healthcare providers do not know that at the ... Today, FDA urged patients,still using chlorofluorocarbon (CFC) albuterol metered-dose ...
... EXTON, Pa., May 30 Isolagen(TM), Inc. (Amex:,ILE) ... notice from the staff,of the American Stock Exchange (AMEX) ... compliance did not demonstrate its ability,to regain compliance with ... (a)(i)-(iii) of the AMEX Company Guide within the,prescribed time ...
Cached Medicine News:Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Mutual Protection Trust Earns Third A+ Rating From A.M. Best 2Health News:Panel Calls for Better Diabetes Screening 2Health News:Get the Facts on the Albuterol Inhaler Transition 2Health News:Get the Facts on the Albuterol Inhaler Transition 3Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 3
(Date:7/28/2015)... -- Research and Markets ( ... "Craniomaxillofacial Implants Market - Global Industry Analysis, ... 2022" report to their offering. ... the current and future prospects of the global ... the global market due to increasing facial deformities ...
(Date:7/28/2015)...  SeraCare Life Sciences, a leading partner to ... the American Association of Clinical Chemistry (AACC) meeting ... the University of California, San Francisco (UCSF) for ... (T18) and Trisomy 13 (T13) trophoblast cell line ... materials for Non-Invasive Prenatal Testing (NIPT) of chromosomal ...
(Date:7/28/2015)... , July 28, 2015  PD-Rx Pharmaceuticals, ... announced that it has partnered with Dobson Technologies, ... as a Service (IaaS) product. PD-Rx ... practices across the United States.  Using Dobson Technologies, ... recovery and business continuity, ensure regulatory compliance, and ...
Breaking Medicine Technology:Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3PD-Rx Partners With Dobson Technologies 2
... Cell Therapy, Inc. ("Pathfinder")(OTCQB: PFND), a biotechnology company focused ... damage, today announced that effective at the start of ... will change from SYMD to PFND.  The new ticker ... and has been approved by the Financial Industry Regulatory ...
... 2011 Cempra Pharmaceuticals today announced abstracts to ... novel fluoroketolide antibiotic, solithromycin (CEM-101), at the ... (ICAAC) , September 17 to 20, 2011, in ... the safety and routes of administration of CEM-101, ...
Cached Medicine Technology:Pathfinder Cell Therapy, Inc. Announces New Stock Ticker Symbol 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 3Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 4Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: